Article
Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.
Expert review of anticancer therapy - 1 May 2026
de Moraes Francisco Cezar Aquino, Matheus Gustavo Tadeu Freitas Uchôa, Rego Luis Henrique Rios Moreira, Sano Vitor Kendi Tsuchiya, Gazabón Jennifer Bayona, Burbano Rommel Mario Rodríguez
Abstract excerpt
INTRODUCTION: Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors such as imatinib, though drug response varies among patients. Genetic polymorphisms in drug transporter genes ABCB1 and ABCG2 influence imatinib plasma trough concentrations (Ctrough). METHODS: Statistical analyses were performed using fixed-effect models and heterogeneity was assessed using I² statistic. RESULTS:...
Topics
Join the communities discussing this publication.